Metabolic syndrome and microangiopathy

Israel Medical Association Journal

Volumn 8, Issue 6, 2006, Pages 424-425

  Szalat, Auryan ^a   Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Endothelial dysfunction; Metabolic syndrome; Microangiopthy; Type 2 diabetes

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LOW CALORY DIET; METABOLIC SYNDROME X; MICROALBUMINURIA; MICROANGIOPATHY; PATHOPHYSIOLOGY; VASCULAR DISEASE;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INSULIN RESISTANCE; ISRAEL; METABOLIC SYNDROME X;

EID: 33745598795     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. IMAJ 2006;8:378-82.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
5. UK Prospective Diabetes Study Group UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317:703-13.
6. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001;16:2486-97.
8. Thomas M, Rosengard-Barlund M, Mills V, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006;29:317-22.
9. Coonrod B, Ellis D, Becker D, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993;16:1376-83.
10. Herrera-Pombo J, Aguilar-Diosdado M, Hawkins F, et al. Is increasing urinary albumin a better marker for microvascular than for macrovascular complication of type 2 diabetes mellitus? Nephron Clin Pract 2005;10:116-21.
11. Wong T, Klein R, Islam F, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006;141:446-55.
12. Tesfaye S, Chaturvedi N, Eaton S, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-50.
13. Jager A, van Hinsbergh V, Kostense P, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002;22:593-8.
14. Kane E, Kim H, Kim Y, et al. Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Res Clin Pract 2004;66:S115-20.
15. Schalkwijk C, Stehouwer C. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 2005;109: 143-59.
16. Sheetz M, King G. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
17. Boulbou M, Koukoulis G, Makri E, Petinaki E, Gourgoulianis K, Germenis A. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 2005;98:39-44.
18. Leclercq B, Jaimes E, Raij L. Nitric oxide synthase and hypertension. Curr Opin Nephrol Hypertens 2002;11:185-9.
19. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.
20. Petersen J, McGuire D. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;2:9-15.